Skip to main content

Table 3 Medications at time of diagnosis of CUA in cases and matched dialysis controls

From: Calciphylaxis epidemiology, risk factors, treatment and survival among French chronic kidney disease patients: a case-control study

Treatment

N

Total CUA cases

N

Non dialysis cases

N

Dialysis cases

N

Dialysis controls

P Value

25-hydroxyvitamin D

89

53 (59.6%)

19

11 (57.9%)

70

42 (60.0%)

137

89 (65.0%)

0.48

Active vitamin D

89

19 (21.4%)

19

3 (15.8%)

70

16 (22.9%)

137

31 (22.6%)

0.97

Calcium-based phosphate binders

89

47 (52.8%)

19

6 (31.6%)

70

41 (58.6%)

137

60 (43.8%)

0.04

Non calcium-based phosphate binders

89

47 (52.8%)

19

4 (21.1%)

70

43 (61.4%)

137

76 (55.6%)

0.41

Sevelamer

89

37 (41.6%)

19

4 (21.1%)

70

33 (47.1%)

137

58 (41.4%)

0.43

Lanthanum carbonate

89

12 (13.5%)

19

1 (5.3%)

70

11 (15.7%)

137

19 (13.6%)

0.68

Cinacalcet

89

17 (19.1%)

19

1 (5.3%)

70

16 (22.9%)

136

26 (19.1%)

0.53

Betablocker

89

54 (60.7%)

19

15 (79.0%)

70

39 (55.7%)

137

65 (47.5%)

0.26

Insulin therapy

89

35 (39.3%)

19

8 (42.1%)

70

27 (38.6%)

138

34 (24.6%)

0.04

Vitamin K Antagonist

89

64 (71.9%)

19

11 (57.9%)

70

53 (75.7%)

138

37 (26.8%)

< 0.001

Fluindione

64

44 (68.8%)

11

6 (54.6%)

53

38 (71.7%)

37

18 (48.7%)

 

Warfarin

64

17 (26.6%)

11

3 (27.7%)

53

14 (26.4%)

37

16 (43.2%)

 

Corticosteroids

89

10 (11.2%)

19

2 (10.5%)

70

8 (11.4%)

138

16 (11.6%)

0.97

Statin

89

46 (51.7%)

19

9 (47.4%)

70

37 (52.7%)

138

71 (51.5%)

0.85

ESA

89

72 (80.9%)

19

9 (47.4%)

70

63 (90.0%)

137

106 (77.4%)

0.03

Iron therapy

89

63 (70.8%)

19

8 (42.1%)

70

55 (78.6%)

137

102 (74.4%)

0.51

ACEi/ARB

89

32 (36.0%)

19

8 (42.1%)

70

24 (34.3%)

138

43 (31.2%)

0.65

Hemodialysis parameters

 HD

    

67

43 (64.2%)

138

91 (65.9%)

 

 HDF

    

67

47 (34.1%)

138

24 (35.8%)

 

 eKt/V

    

62

1.40 (1.06–1.67)

131

1.53 (1.33–1.82)

< 0.001

 Citrate

    

67

10 (14.3%)

138

20 (14.3%)

1.00

  1. Median (IQR) or N (%). P-Value of comparison of Dialysis Cases with Dialysis controls. ACEi/ARB angiotensin converting enzyme inhibitor/angiotensin receptor blocker; ESA erythropoiesis-stimulating agent, HD hemodialysis, HDF hemodiafiltration